Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cerebral Infarction | 1 | 2018 | 245 | 0.58 | Why? |
| Neovascularization, Pathologic | 1 | 2018 | 305 | 0.55 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2020 | 10649 | 0.48 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.34 | Why? |
| Zoonoses | 1 | 2020 | 3034 | 0.30 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.29 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.27 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.25 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.22 | Why? |
| Antibodies, Viral | 8 | 2020 | 51949 | 0.22 | Why? |
| Quasispecies | 1 | 2021 | 108 | 0.21 | Why? |
| Antibodies, Neutralizing | 4 | 2020 | 25288 | 0.20 | Why? |
| Lymphocytic Choriomeningitis | 1 | 2019 | 43 | 0.20 | Why? |
| T-Box Domain Proteins | 1 | 2019 | 62 | 0.20 | Why? |
| Lymphocytic choriomeningitis virus | 1 | 2019 | 98 | 0.19 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.18 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.18 | Why? |
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 190 | 0.18 | Why? |
| Immunoenzyme Techniques | 1 | 2020 | 448 | 0.17 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.17 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 347 | 0.15 | Why? |
| Germinal Center | 1 | 2019 | 332 | 0.15 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 372 | 0.15 | Why? |
| MAP Kinase Signaling System | 1 | 2018 | 360 | 0.15 | Why? |
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 291 | 0.15 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 497 | 0.15 | Why? |
| Th1 Cells | 1 | 2021 | 1228 | 0.14 | Why? |
| Hepatitis B, Chronic | 1 | 2020 | 616 | 0.13 | Why? |
| Ribavirin | 1 | 2020 | 1182 | 0.12 | Why? |
| Interferon-alpha | 1 | 2020 | 1442 | 0.11 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.10 | Why? |
| Rats | 1 | 2018 | 2764 | 0.10 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.10 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.09 | Why? |
| Immunoglobulin M | 3 | 2020 | 9091 | 0.09 | Why? |
| Research | 1 | 2021 | 2115 | 0.09 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.08 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.08 | Why? |
| Antibody Formation | 1 | 2020 | 4038 | 0.08 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.08 | Why? |
| Gene Expression Regulation | 1 | 2019 | 4020 | 0.08 | Why? |
| Pandemics | 11 | 2020 | 389249 | 0.08 | Why? |
| B-Lymphocytes | 1 | 2021 | 4418 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Humans | 16 | 2021 | 930598 | 0.06 | Why? |
| Immunoglobulin G | 3 | 2020 | 21571 | 0.06 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.06 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.05 | Why? |
| Animals | 3 | 2020 | 78931 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| Convalescence | 2 | 2020 | 2829 | 0.05 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.04 | Why? |
| Cloning, Molecular | 1 | 2020 | 1036 | 0.04 | Why? |
| Virus Activation | 1 | 2020 | 480 | 0.04 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Aged | 6 | 2021 | 215776 | 0.04 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.04 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.03 | Why? |
| Liver Function Tests | 1 | 2020 | 1325 | 0.03 | Why? |
| Mice, Knockout | 1 | 2019 | 1815 | 0.03 | Why? |
| Base Sequence | 1 | 2021 | 3581 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Cell Differentiation | 1 | 2019 | 1338 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Female | 9 | 2021 | 380317 | 0.03 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3633 | 0.02 | Why? |
| Apoptosis | 1 | 2019 | 2335 | 0.02 | Why? |
| Peptides | 1 | 2020 | 2513 | 0.02 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.02 | Why? |
| HEK293 Cells | 1 | 2020 | 8394 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.02 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Mice | 1 | 2019 | 21357 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
Chen's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(98)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(219)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_